Clinical Trial
Journal Article
Add like
Add dislike
Add to saved papers

Changes in liver biochemical tests at diagnosis and after propylthiouracil therapy for hyperthyroidism.

We investigated liver biochemical tests at diagnosis and after a 6-week treatment with propylthiouracil (PTU) in forty-three patients with hyperthyroidism. At diagnosis, 60.5% of the patients had at least one liver biochemical abnormality. Elevation of alkaline phosphatase (ALP), alanine (ALT) and aspartate (AST) aminotransferase, and gamma-glutamyl transpeptidase (GGT) levels were observed in 19 (44.2%). 10 (23.3%), 6 (14%) and 6 (14%) of the patients, respectively. After 6-week treatment with PTU, seven (16.3%) patients developed subclinical hepatotoxicity, as evidenced by elevation of ALT levels. Age, sex, type of goiter (either diffuse or multinodular) and presence or absence of abnormal liver biochemical tests at diagnosis were not significant in determining the possibility of the development of hepatotoxicity. These data suggest that liver biochemical test abnormalities are frequently observed in hyperthyroid. However, presence or absence of these abnormalities do not indicate to the development of subclinical hepatoxicity during 6-week PTU therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app